Browse Category

NYSE:JNJ News 31 January 2026 - 7 February 2026

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
5 February 2026
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 2 3 11

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop